Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367301 · ClinicalTrials.gov registry record · NA
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
A NA study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01367301: Clinical Trial NA study, sponsored by Albert Einstein College of Medicine.
NCT01367301 is a NA study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01367301, a NA study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.
Primary Outcome
One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION intensity-modulated radiation therapy
- RADIATION brachytherapy
- RADIATION external beam radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-07-08 |
| Est. Completion | 2018-08-15 |
| Phase | NA |
Why NCT01367301 stopped before completion
NCT01367301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT01367301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01367301 about?
NCT01367301 is a clinical study titled "Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer". This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor...
What is the current status of trial NCT01367301?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2011-07-08. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT01367301?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), intensity-modulated radiation therapy (RADIATION), brachytherapy (RADIATION), external beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01367301?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01367301's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy